FDA Starts Phase II of Efforts to Reduce Salt Levels in Food
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Aug. 15, 2024 -- The U.S. Food and Drug Administration on Thursday announced Phase II of its initial efforts to cut dietary salt intake by Americans.
U.S. Dietary Guidelines recommend that a person consume no more than 2,300 mg of sodium per day, the equivalent of about one teaspoon of salt. However, Americans typically take in far higher amounts than recommended, averaging about 3,400 mg/day before 2021, the FDA noted in a news release.
Phase 1 of the FDA voluntary sodium-reduction targets for the food industry were issued in 2021, and according to the agency, "preliminary data from 2022 show about 40 percent of the initial Phase I targets are very close to or have already been reached, indicating early success of this effort."
That level of success has spurred the agency to begin Phase II.
"If finalized, the new set of voluntary targets would support reducing average individual sodium intake to about 2,750 mg per day," the FDA said.
The new initiative is expected to coincide with the U.S. Department of Agriculture efforts to limit sodium in school meals.
"Reducing sodium in the food supply has the potential to be one of the most important public health initiatives in a generation," Jim Jones, FDA deputy commissioner for human foods, said in the agency statement. "The early successes we're seeing with sodium level reduction in certain foods is encouraging and indicative of the impact we believe our overall nutrition approach can have on the well-being of society."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-16 07:15
Read more
- AHA: Rising Outdoor Temperatures Tied to Higher Risk for Atrial Fibrillation
- Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
- Rising Temperatures Increase Risk for Poor Maternal, Neonatal Outcomes
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
- ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
- COVID-19 Mortality Higher for Leukemia, Myelodysplastic Syndrome Patients
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions